Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ACP-211

Other · developed by ACADIA Pharmaceuticals

Phase 2 Most advanced trial
ACAD Developer
1 Registered trials

What is ACP-211?

ACP-211 is an investigational drug studied in Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant.

At a glance

Drug type
Other
Therapy area
Psychiatry
Developer
ACADIA Pharmaceuticals Inc. (ACAD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07284667 Phase 2 Major Depressive Disorder (MDD) Recruiting ACAD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Depressive Disorder, Treatment-ResistantMajor Depressive Disorder (MDD)

More from ACADIA Pharmaceuticals

Pimavanserin FDA approved ACP-044 Phase 2 ACP-104 Phase 2 ACP-204 Phase 3 Carbetocin Phase 3

Follow ACAD, the company behind ACP-211

See ACAD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACAD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.